Rocky Mountain Cancer Centers
Oncology
Dr. Allen L. Cohn, MD
|
|
Give Review
Dr. Allen L. Cohn is an expert in the field of Oncology. He attended University of Maryland School of Medicine. University of Maryland School of Medicine has a rank of 37 in research and a 52 in primary care He received 2 awards: "Meaningful Use Stage 1 Certification" and "CORE Magazine". Allen Cohn is a published doctor and has 27 publications published. The lastest was: 'Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.' He accepts Medicare.
Publications
- Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
- A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer.
- Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.
- Safety and Effectiveness of Bevacizumab Treatment for Metastatic Colorectal Cancer: Final Results from the Avastin(®) Registry - Investigation of Effectiveness and Saf...
- Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomise...
- TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
- Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised ...
- A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal c...
- Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study.
- A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
- An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
- Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
- A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma.
- External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Onco...
- Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TR...
- Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer.
- Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
- Cryodestruction of hepatic tumors.
- An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.
- Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma.
- A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer.
- Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.
- A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer.
- An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.
- A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
- Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Schools
University Of Maryland Medical System
University Of Colorado
Procedures Preformed
- Breast Cancer Treatment
- Cancer Counseling
- Cancer Pain Management
- Cancer Treatment
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
- CORE Magazine
Education
-
University of Colorado -
University of Maryland School of Medicine
Hospital
-
Sky Ridge Medical Center
Drug Facts
| NPI NUMBER | 1316921976 | |
| NPPES Provider LastName | COHN | |
| NPPES Provider FirstName | ALLEN | |
| NPPES Provider ZIPCode | 802181234 | |
| NPPES Provider State | CO | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 997.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 149.0 | |
| Percent Opioid Claims | 14.94 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1316921976 |
| Last Name Of The Provider | COHN |
| First Name Of The Provider | ALLEN |
| View All |
Similar Doctors
|
Dr. Alan H. Tralins, MD |
|
|
Dr. Douglass C. Tormey, MD |